Microsoft (NASDAQ: MSFT) stock has advanced from $204 above $223 in less than several weeks and the current price stands around $213. Microsoft has found strong support above $200 but the price is still not able to surpass $230 resistance. Fundamental analysis: The pandemic has only solidified the position of Microsoft further Even with the COVID-19 pandemic, the business of Microsoft is going well and the company will have a rise in revenue for the next fiscal year. Microsoft launched Azure Communication Services recently that will compete with Twilio and Amazon. This service allows developers to add video, voice, chat,
Full ArticleMicrosoft stock price gains ahead of Q1 earnings results
Invezz
0 shares
1 views
You might like
Related news coverage
Alphabet, Google's parent company, sees shares rise after its third-quarter sales growth beat analysts’ estimates
Proactive Investors
Alphabet Inc (NASDAQ:GOOG), Google's parent company, saw its shares rise on Friday after its third-quarter sales growth..
-
Alphabet, Google's parent company, sees shares rise after its third-quarter sales growth beats analysts’ estimates
Proactive Investors
-
US stocks end mixed session on rising COVID-19 rates and stimulus impasse
Proactive Investors
-
Wall Street mixed at midday as Nasdaq flies ahead of the Dow
Proactive Investors
-
US stocks end lower as potential coronavirus treatments hit a roadblock
Proactive Investors
Advertisement
More coverage
Wall Street remains mixed with Nasdaq pushing higher
Proactive Investors
12:20 pm: Dow down 100 at midday The Dow Jones Industrial Average dropped 91 points, 0.3%, to 28,746.2, and the S&P 500 fell 10..
-
Wall Street opens on a mixed note with Nasdaq pushing higher
Proactive Investors
-
US indices to open mostly lower with Nasdaq the outlier
Proactive Investors
-
NA Proactive news snapshot: CleanSpark, Field Trip Health, DGTL Holdings, Vuzix, Phunware UPDATE …
Proactive Investors
-
NA Proactive news snapshot: ElectraMeccanica, AIM ImmunoTech, Energy Fuels, Tectonic Metals, American Rebel, Biocept UPDATE…
Proactive Investors